Neurocognitive changes in a patient receiving esketamine for treatment-resistant depression.
Carolyn F Kundert, Robert M Sobule, Muaid Ithman
JAAPA : official journal of the American Academy of Physician Assistants September 1, 2024 DOI: 10.1097/01.JAA.0000000000000036 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A patient whose neurocognitive symptoms worsened with esketamine treatment |
| Topics | Depression Esketamine Ketamine |
| Keywords | Depression treatment Cognitive side effects Esketamine therapy Mental health research Brain function |
| Citations | 1 |
| Key findings | Neurocognitive symptoms worsened with esketamine treatment, necessitating discontinuation. |
Abstract
Esketamine, the s(+) enantiomer of ketamine, was approved in 2019 as the first rapid-acting intranasal spray medication for treatment-resistant depression; the drug is given in combination with an antidepressant. The treatment is self-administered in a clinical setting under the supervision of a healthcare provider and usually is well tolerated. Many of its adverse reactions are mild, temporary, and dose-dependent, and they improve with subsequent treatments. Although the prescribing information lists difficulty remembering or thinking as possible adverse reactions, a neurocognitive evaluation is not part of the initial patient evaluation. This case report focuses on a patient whose neurocognitive symptoms worsened with esketamine treatment, necessitating treatment discontinuation.
Comparable studies
Other case reports and case series on esketamine for depression, most cited first.